Even some of the industry's stalwarts are showing signs of stress.
With a toxic cocktail of the market and economic factors in play, it's a risky bet.
All of these companies are trading at low price-to-book-value ratios.
If you thought 2022 was harsh, just wait.
Marijuana-related stocks reversed gains from earlier in the week as revelations emerged that a recent marijuana bill is unlikely to pass.
All three are pursuing strategies that are working and will work even better in the long term.
These stocks may not stay this cheap for long.
Legal barriers are falling, and the North American market is set to be in flux.
Wall Street was upbeat in October with major key U.S. indexes offering massive gains, except for the Nasdaq, which recorded muted gains.
It probably won't sink them alone, but it won't help much either.
